Interpreting the CYP2D6 Results From the International Tamoxifen Pharmacogenetics Consortium.

Interpreting the CYP2D6 Results From the International Tamoxifen Pharmacogenetics Consortium.
Clin Pharmacol Ther. 2014 Aug;96(2):144-6
Authors: Province MA, Altman RB, Klein TE
Abstract
UNLABELLED: Meta-analysis of the entire analyzable cohort of 4,935 tamoxifen-treated breast cancer patients by the International Tamoxifen Pharmacogenetics Consortium (ITPC) (criterion 3) revealed no CYP2D6 effect on outcomes but strong heterogeneity across sites.(1) However, a post hoc-defined subgroup (criterion 1: postmenopausal, estrogen receptor positive, receiving 20 mg/day tamoxifen for 5 years; n = 1,996) did find a statistically significant effect of CYP2D6 on both invasive disease-free survival as well as breast cancer-free interval, with little site heterogeneity. How should we interpret these discrepant findings?"
STATISTICS: The only science that enables different experts using the same figures to draw different conclusions."-Evan Esar, humorist"Data do not give up their secrets easily. They must be tortured to confess."-Jeffrey Hooper, Bell Laboratories"Facts are stubborn, but statistics are more pliable."-Mark Twain, humorist.
PMID: 25056393 [PubMed - in process]

Source: Clinical Breast Cancer - July 28, 2014 Category: Cancer & Oncology Authors: Province MA, Altman RB, Klein TE Tags: Clin Pharmacol Ther Source Type: research